Vaccine Targeting Alpha 1D-Adrenergic Receptor Improved Metabolic Syndrome in Mice

[1]  H. Assi,et al.  Metabolic Syndrome: Updates on Pathophysiology and Management in 2021 , 2022, International journal of molecular sciences.

[2]  D. Perez.  Current Developments on the Role of α1-Adrenergic Receptors in Cognition, Cardioprotection, and Metabolism , 2021, Frontiers in Cell and Developmental Biology.

[3]  T. Gojobori,et al.  Leptin and Obesity: Role and Clinical Implication , 2021, Frontiers in Endocrinology.

[4]  J. Friedman,et al.  A leptin–BDNF pathway regulating sympathetic innervation of adipose tissue , 2020, Nature.

[5]  H. Fengyang,et al.  Chronic diabetes and hypertension impair the in vivo functional response to phenylephrine independent of α1-adrenoceptor expression. , 2020, European journal of pharmacology.

[6]  E. Vidal-Petiot,et al.  Adrenergic receptors and cardiovascular effects of catecholamines. , 2020, Annales d'endocrinologie.

[7]  H. Seo,et al.  Stimulation of Alpha1-Adrenergic Receptor Ameliorates Cellular Functions of Multiorgans beyond Vasomotion through PPARδ , 2020, PPAR research.

[8]  Xijun Chen,et al.  Immunotherapy of Endothelin-1 Receptor Type A for Pulmonary Arterial Hypertension. , 2019, Journal of the American College of Cardiology.

[9]  Kavita Sharma,et al.  Nitrosative stress drives heart failure with preserved ejection fraction , 2019, Nature.

[10]  M. Saklayen.  The Global Epidemic of the Metabolic Syndrome , 2018, Current Hypertension Reports.

[11]  J. Ching,et al.  Macrophage VLDLR mediates obesity-induced insulin resistance with adipose tissue inflammation , 2017, Nature Communications.

[12]  Hailang Wu,et al.  A Therapeutic Peptide Vaccine Against PCSK9 , 2017, Scientific Reports.

[13]  A. Heydemann.  An Overview of Murine High Fat Diet as a Model for Type 2 Diabetes Mellitus , 2016, Journal of diabetes research.

[14]  Ana I. Domingos,et al.  Sympathetic Neuro-adipose Connections Mediate Leptin-Driven Lipolysis , 2015, Cell.

[15]  Vitaly Ryu,et al.  Neural innervation of white adipose tissue and the control of lipolysis , 2014, Frontiers in Neuroendocrinology.

[16]  S. Samson,et al.  The Metabolic Syndrome: A Common Hyperinsulinemic Disorder With Severe Health Effects , 2006 .

[17]  R. Campos-Rodríguez,et al.  Effect of Early Diabetes on the Expression of Alpha-1 Adrenergic Receptors in Aorta and Carotid Arteries of Wistar Kyoto and Spontaneously Hypertensive Rats , 2013, Clinical and experimental hypertension.

[18]  L. Sobrevia,et al.  Mice Long-Term High-Fat Diet Feeding Recapitulates Human Cardiovascular Alterations: An Animal Model to Study the Early Phases of Diabetic Cardiomyopathy , 2013, PloS one.

[19]  Gregory Kaltsas,et al.  Metabolic syndrome: definitions and controversies , 2011, BMC medicine.

[20]  S. Daubner,et al.  Tyrosine hydroxylase and regulation of dopamine synthesis. , 2011, Archives of biochemistry and biophysics.

[21]  T. Tagami,et al.  ORIGINAL ARTICLE: Monoclonal autoantibodies to the TSH receptor, one with stimulating activity and one with blocking activity, obtained from the same blood sample , 2010, Clinical endocrinology.

[22]  J. Dixon,et al.  Sympathetic nervous activation in obesity and the metabolic syndrome--causes, consequences and therapeutic implications. , 2010, Pharmacology & therapeutics.

[23]  O. McGuinness,et al.  NIH experiment in centralized mouse phenotyping: the Vanderbilt experience and recommendations for evaluating glucose homeostasis in the mouse. , 2009, American journal of physiology. Endocrinology and metabolism.

[24]  J. McGill,et al.  Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients , 2009, Diabetes, obesity and metabolism.

[25]  R. Freeman,et al.  Leptin: Linking obesity, the metabolic syndrome, and cardiovascular disease , 2008, Current hypertension reports.

[26]  P. Raskin,et al.  Differential effect of β‐blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI , 2007, Diabetic medicine : a journal of the British Diabetic Association.

[27]  W. Wahli,et al.  Transcriptional regulation of metabolism. , 2006, Physiological reviews.

[28]  R. Tallarida,et al.  Changes in Aorta Alpha1-Adrenoceptor Number and Affinity during One Year of Streptozotocin-Induced Diabetes in Rats , 2005, Pharmacology.

[29]  G. Tsujimoto,et al.  Two α1-Adrenergic Receptor Subtypes Regulating the Vasopressor Response Have Differential Roles in Blood Pressure Regulation , 2005, Molecular Pharmacology.

[30]  Francesca Fanelli,et al.  Synthesis, Screening, and Molecular Modeling of New Potent and Selective Antagonists at the α1d Adrenergic Receptor , 2004 .

[31]  M. Bachmann,et al.  Therapeutic vaccination for chronic diseases: a new class of drugs in sight , 2004, Nature Reviews Drug Discovery.

[32]  G. Shulman,et al.  Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and β‐cell dysfunction , 2002, European journal of clinical investigation.

[33]  Barry R. Davis,et al.  Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. , 2000, JAMA.

[34]  G. Bray.  Obesity, a disorder of nutrient partitioning: the MONA LISA hypothesis. , 1991, The Journal of nutrition.

[35]  I. Meredith,et al.  Overflow of catecholamine neurotransmitters to the circulation: source, fate, and functions. , 1990, Physiological reviews.

[36]  G. Francis,et al.  Modulation of peripheral sympathetic nerve transmission. , 1988, Journal of the American College of Cardiology.